Ryan Deschner
Stock Analyst at Raymond James
(4.82)
# 99
Out of 5,015 analysts
17
Total ratings
76.47%
Success rate
47.92%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Ryan Deschner
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LQDA Liquidia | Maintains: Strong Buy | $33 → $41 | $23.19 | +76.80% | 4 | Aug 13, 2025 | |
| TRVI Trevi Therapeutics | Maintains: Strong Buy | $29 → $27 | $9.99 | +170.27% | 3 | Aug 8, 2025 | |
| PVLA Palvella Therapeutics | Initiates: Outperform | $54 | $69.90 | -22.75% | 1 | Aug 6, 2025 | |
| ARDX Ardelyx | Maintains: Outperform | $11 → $12 | $4.94 | +142.91% | 2 | Aug 5, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $52 → $50 | $25.12 | +99.04% | 2 | Aug 1, 2025 | |
| VKTX Viking Therapeutics | Maintains: Strong Buy | $125 → $122 | $33.56 | +263.53% | 1 | Jul 24, 2025 | |
| TVRD Tvardi Therapeutics | Initiates: Outperform | $62 | $41.41 | +49.72% | 1 | Jul 14, 2025 | |
| SPRY ARS Pharmaceuticals | Maintains: Strong Buy | $26 → $28 | $11.32 | +147.35% | 3 | Jan 14, 2025 |
Liquidia
Aug 13, 2025
Maintains: Strong Buy
Price Target: $33 → $41
Current: $23.19
Upside: +76.80%
Trevi Therapeutics
Aug 8, 2025
Maintains: Strong Buy
Price Target: $29 → $27
Current: $9.99
Upside: +170.27%
Palvella Therapeutics
Aug 6, 2025
Initiates: Outperform
Price Target: $54
Current: $69.90
Upside: -22.75%
Ardelyx
Aug 5, 2025
Maintains: Outperform
Price Target: $11 → $12
Current: $4.94
Upside: +142.91%
Apellis Pharmaceuticals
Aug 1, 2025
Maintains: Outperform
Price Target: $52 → $50
Current: $25.12
Upside: +99.04%
Viking Therapeutics
Jul 24, 2025
Maintains: Strong Buy
Price Target: $125 → $122
Current: $33.56
Upside: +263.53%
Tvardi Therapeutics
Jul 14, 2025
Initiates: Outperform
Price Target: $62
Current: $41.41
Upside: +49.72%
ARS Pharmaceuticals
Jan 14, 2025
Maintains: Strong Buy
Price Target: $26 → $28
Current: $11.32
Upside: +147.35%